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Clusterin mRNA levels were shown to increase dramatically
in rat ventral prostate following castration, and clusterin was
therefore originally thought to be repressedby androgens. Itwas
later discovered that the increased clusterin levels are most
likely due to castration-induced apoptosis of the prostatic epi-
thelium rather than direct action of the androgen receptor (AR).
In the studies presented here, LNCaP cells in culture and rat
prostate organ culture were treated with androgens. Clusterin
mRNA and protein are shown to increase with androgen treat-
ment in a time- and dose-dependent manner. This induction of
clusterin requires AR and can be inhibited by casodex, an AR
antagonist. We have found that the first intron of the clusterin
gene contains putative androgen response elements. The
intronic region is shown to be bound byAR in chromatin immu-
noprecipitation assays and is transactivated by AR in reporter
assays. Two isoforms of clusterin result from alternate tran-
scriptional start sites. Both isoforms are cytoprotective; how-
ever, Isoform1has the capacity toproduce a splice variant that is
apoptotic. Real time PCRwas used to determine the response of
the two isoforms to androgens. Intriguingly, these results illus-
trated that Isoform 2 was up-regulated, whereas Isoform 1 was
down-regulated by androgens. Isoform 2 was also increased as
the LNCaP xenograft tumor progressed to androgen-indepen-
dence, whereas Isoform 1 was unaltered. This androgen regula-
tion of clusterinmay underline the cytoprotective role of andro-
gens in normal prostate physiology as well as play an
antiapoptotic role in prostate cancer progression.
Clusterin, also known as TRPM-2 (testosterone-repressed
prostatemessage), ApoJ, and SPG-2, is a heterodimeric sulfated
glycoprotein, first isolated in ram rete testis fluid (1, 2). Clus-
terin iswidely expressed inmany tissues, including brain, ovary,
testis, liver, heart, lung, breast, and prostate (3), and appears to
be involved in a diverse number of biological processes. There is
evidence that clusterin can act as a molecular chaperone (4),
and it has been implicated in tissue remodeling (5), lipid trans-
port (6, 7), cell-cell interactions (8), sperm maturation (9), and
apoptosis (10). However, the exact role of clusterin in many of
these processes remains unclear.
Upon castration, the prostatic epithelial cells undergo apo-
ptosis in rat ventral prostate, and clusterin mRNA levels are
greatly increased (11, 12); therefore, clusterin was originally
thought to be repressed by testosterone. Clusterin also
increases in the androgen-dependent Shionogi tumormodel, in
which castration causes a rapid apoptotic response following
castration (13). However, in later studies it was shown that in
mice bearing Shionogi tumors, when treated with calcium
channel blockers that prevent apoptosis, clusterin is not up-
regulated in the absence of testicular androgens (14). Similarly,
if the rate of prostatic atrophy is decreased using glucocorticoid
treatment, clusterin mRNA levels are reduced (15). Therefore,
the current understanding is that clusterin induction is associ-
ated with apoptosis rather than an androgen-repressed gene.
Clusterin has been a somewhat enigmatic protein, being
described as being both proapoptotic (16, 17) and antiapoptotic
(18, 19). It was later discovered that the differential translation
and post-translational processing result in either a secreted or
nuclear clusterin. The secreted form of clusterin has been
shown to be cytoprotective, whereas the nuclear form is pro-
apoptotic (20, 21). An alternative splicing event generates
nuclear clusterin (21–23). This splicing event removes the ER3-
targeting signal and allows the protein to be transported into
the nucleus using a nuclear localization sequence (21).
Recent updates to GenBankTM have highlighted that there
are two transcriptional isoforms of human clusterin (Isoform 1,
NM_001831; Isoform 2, NM_203339). These isoforms result
from different transcriptional initiation sites and are only pro-
duced in humans and chimpanzees. These transcriptional iso-
forms result in proteins that have different N termini. Both
clusterin isoforms produce proteins that are cytoprotective.4
Intriguingly, it is only Isoform 1 that is capable of producing a
splice variant that results in the nuclear, apoptotic form of clus-
terin (21). Many studies demonstrating that clusterin has anti-
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apoptotic properties have been undertaken in mice or rats, and
these species are only capable of transcribing the orthologue to
Isoform 1 of clusterin; however, the first exon is predicted to
not be translated due to the lack of an initiating methionine in
nonprimate species.
Clusterin is expressed in many cancers, including breast,
prostate, ovarian, pancreatic, and renal cancers (25–29). In
prostate cancer, high levels of clusterin correlate with Gleason
grade (30), which may suggest that clusterin plays a role in the
aggressiveness of a tumor. The levels of clusterin increase sig-
nificantly following androgen ablation therapy (31). Clusterin
provides a route by which a subset of the prostate cancer cells
can evade apoptosis due to androgen ablation and thereby
allows the cells to grow into androgen-independent (AI) can-
cer. In xenografts of LNCaP cells overexpressing clusterin, the
tumors reach androgen independence faster than the parental
cell line, suggesting that clusterin plays a role in the acquisition
of the AI phenotype (11).
Prostate cells overexpressing Isoform 2 of clusterin become
more resistant to Fas-mediated apoptosis (32). Oligonucleo-
tides that target Isoform 2 of clusterin endow the cells with
sensitivity to radiation (33) and chemotherapeutic agents (34).
In the present study, we show that total clusterin expression
is in fact up-regulated by androgens. In an androgen-dependent
prostate cancer cell line, clusterin is up-regulated at both the
RNA and protein levels when treated with androgens, and this
effect is reversed with anti-androgen treatment. Clusterin
mRNA levels are also seen increasing in rat ventral prostate
organ culture when treated with androgens. This effect is spe-
cific to androgens, since exposure to other steroid hormones
does not have an effect on clusterin levels.We show that theAR
directly regulates clusterin expression through interactionwith
an intronic enhancer region on the clusterin gene. Further-
more, androgens have opposing effects on the two mRNA iso-
forms of clusterin that are generated fromalternative start sites.
Isoform 1 is repressed by androgens, whereas Isoform 2 is up-
regulated by androgens through direct interactionwith the first
intron.
EXPERIMENTAL PROCEDURES
Cell Culture—LNCaP cells (passage 35–50) and PC3 cells
(passage 10–20) were grown at 37 °C and 5% CO2 in RPMI and
Dulbecco’s modified Eagle’s medium, respectively, both con-
taining 5% fetal bovine serum and penicillin/streptomycin.
Charcoal-stripped serum (CSS) is prepared using fetal calf
serum incubated with 1% charcoal and 0.1% dextran T-70 fol-
lowed by filtration.
Hormone Treatments—R1881, dihydrotestosterone (DHT),
and dexamethazone were purchased from Steraloids Inc. Pro-
gesterone, 17-estradiol (estradiol), all-trans-retinoic acid, and
3,3,5-triiodo-L-thyronine sodium salt are from Sigma. Caso-
dex (bicalutamide) was from Astro Zenica. All hormone stock
solutions were in absolute ethanol with the exception of the
3,3,5-triiodo-L-thyronine sodium salt, which was dissolved in
NaOH. Prior to any hormone treatments, cells were grown in
media plus 2%CSS for 48 h.Cellswere harvested for protein using
radioimmune precipitation lysis buffer (150 mM NaCl, 1% Ige-
pal, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris) and for
RNA using Trizol (Invitrogen).
NorthernBlotAnalysis—Total RNA (10g)was denatured in
sample buffer and run through a denaturing 1%MOPS formal-
dehyde-agarose gel for 1 h at 80 V. The RNAwas transferred to
a nylonmembrane (Biodyne B; Pall Gelman Laboratory) in 20
SSC (3M sodiumchloride, 0.3 M sodiumcitrate, pH7.0) for 20 h.
The RNA was cross-linked to the membrane using a UV Str-
atalinker (Stratagene) according to the manufacturer’s instruc-
tions. Membranes were prehybridized in ExpressHyb (Clon-
tech), containing denatured salmon testes DNA (Sigma) for 3 h
at 65 °C. Clusterin probes were generated using reverse tran-
scription-PCR from human kidney RNA using the following
primers: 5-AAGGAAATTCAAAAATGCTGTCAA-3 and 5-
ACAGACAAGATCTCCCGGCACTT-3. Radioactivity was
incorporated into the probe using Ready-To-Go DNA labeling
beads (Amersham Biosciences) to a specific activity of 1–2 
108 disintegrations/min/g. Probes were hybridized to the
membrane overnight at 65 °C. High stringency washes were
performed on the membranes at 65 °C. The membranes were
exposed to Eastman Kodak Co. MR film.
Western Blot Analysis—Protein sample (15 g) was boiled at
95 °C for 5 min in sample buffer containing -mercaptoetha-
nol. Samples were loaded on 10% polyacrylamide gels and sub-
jected to electrophoresis for 1 h at 150 V. Proteins were trans-
ferred electrophoretically onto polyvinylidene difluoride
membrane (Millipore). Blots were probed for clusterin using a
goat polyclonal clusterin- (C-18) antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA). After incubation with a sec-
ondary antibody, the membranes were incubated with ECL
reagents (Amersham Biosciences) and exposed to Eastman
Kodak Co. Blue XB-1 film. For normalization purposes, mem-
branes were reprobed with a rabbit polyclonal -tubulin anti-
body (Santa Cruz Biotechnology).
Real Time PCR—Toquantitatively evaluate the levels of clus-
terin in the samples, real time PCR was undertaken. Before
generating the cDNA, 2g of the RNAwas treatedwithDNAse
1 (Invitrogen) to remove any DNA contamination. The RNA
was then reverse transcribed into cDNA in a reaction contain-
ing 1 reaction buffer, 0.01 M dithiothreitol, 1 mM dNTPs, 40
units RNAsin (Promega), random hexamers (250 ng), and 200
units of Moloney murine leukemia virus reverse transcriptase
(Invitrogen). The reaction proceeded at 25 °C for 10 min and
then at 37 °C for 1 h. The levels of clusterin transcript were then
assayed using real time PCR on the ABI 7900 HT sequence
detection system. To determine the levels of total clusterin, a
region of exon 3 was amplified. The primers used were as follows:
forward, 5-GAGCAGCTGAACGAGCAGTTT-3; reverse, 5-
CTTCGCCTTGCGTGAGGT; probe, 5-6-FAM-ACTGGGTG-
TCCCGGCTGGCA-TAMRA-Q-3. To differentiate Isoform 1
and 2 levels, primers and probes in the unique 5-untranslated
regions of the respective transcripts were used as follows: for Iso-
form 1, forward primer 5-CGTGAGTCATGCAGGTTTGC-3,
reverse primer 5-CTGGGAGGCGCCGAAT-3, and probe 5-
6-FAM-TGTGTGCGCGAGCAGAGCGCTAT-TAMRA-Q-3;
for Isoform 2, forward primer 5-CTCTACTCTCCGAAGGG-
AATTGTC-3, reverse primer 5-CGGGCTGCCTGTGCAT-3,
and probe 5-6-FAM-TTCCTGGCTTCCACTACTTCCAC-
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CCC-TAMRA-Q-3. For normalization purposes, rRNA control
primers and probes (ABI) were used. The reported values are the
averages and S.D. values of three biological replicates.
Organ Culture—Young adult male Harlan Sprague-Dawley
rats (250–300 g) fromHarlan, Inc. (Indianapolis, IN) were cas-
trated by removing testes, fat pads, and epididymis in a room
dedicated for animal manipulation according to a protocol
approved by theNorthwesternUniversityAnimalCare andUse
Committee (Chicago, IL). The castrated animals were main-
tained in the Northwestern University animal facility. The ven-
tral prostate was dissected out from the rats 7 days after castra-
tion. Organ culture was done as described previously (35, 36).
Briefly, the prostates were minced with a scalpel to generate
uniform fragmentswith1mm in all dimensions. The prostate
fragmentswere placed on lens paper supported at themedia-air
interface with a stainless steel screen in a 10-cm culture plate
and incubated in 5% CO2 incubator at 37 °C. The prostate frag-
ments were in good contact with the medium but not sub-
merged in the M-199 medium consisting of Earles salts, L-glu-
tamine, and 2.2 g/liter sodiumbicarbonate, without phenol red,
from Invitrogen, with the addition of 10% charcoal-stripped,
penicillin G sodium at 200 units/ml and streptomycin sulfate at
0.2 g/ml. Treatment with DHT was at 1 M final concentra-
tion for 24 h. After treatment, the prostate fragments were har-
vested and frozen immediately in liquid nitrogen N2, and the
RNA was isolated using the guanidinium/CsCl gradient
method. Northern blot analysis of clusterin mRNAwas carried
out as described as previously using a clusterin cDNA probe.
Transfections—LNCaP cells were grown to 60% confluence
before being transfected with 1.5 g of the steroid receptor
expression vectors. Prior to the transfections, cells were grown
in RPMI 2%CSS for 2 days. Lipofectin (Invitrogen) was incu-
bated with serum-free RPMI for 30 min before the DNA was
added and incubated for 10 min more. Cells were transfected
with Lipofectin/DNA mix for 5 h before the medium was
changed to RPMI  2% CSS. Cells were treated with a 1 nM
concentration of the indicated hormone ligand for 72 h prior to
harvesting unless otherwise indicated.
Luciferase Assay—Consite (available on the World Wide
Web at mordor.cgb.ki.se/cgi-bin/CONSITE/consite/) (37) was
used to predict the location of androgen response elements
(AREs) in the clusterin gene. Luciferase reporter plasmids were
created by cloning the PCR-generated fragments into pTK-luc
(ATCC). Both LNCaP and PC3 cells were plated into 6-well
plates, and then using Lipofectin, the cells were transfected
with 3 g of reporter plasmid, 2 g of rat AR in pRcCMV
(Invitrogen), and 0.05 g of the Renilla expression plasmid
pRLTKS (Promega) per plate. After transfection, the cells were
incubated with either 2% CSS medium alone or with R1881.
Cells were washed and harvested with passive lysis buffer (Pro-
mega). PC3 cells were harvested after 48 h of hormone treat-
ment, and LNCaP cells were harvested after 72 h. Luciferase
activity of 20l aliquots of lysate was determined using the dual-
luciferase reporter assay system (Promega) on a luminometer
(Berthold,Germany). Luciferase activitywasnormalized for trans-
fection efficiency usingRenilla activity. Experiments were done in
triplicate, averaged, and expressed as -fold induction.
Chromatin Immunoprecipitation—Plates of LNCaP cells
were incubated with formaldehyde at a concentration of 1% for
10min on a shaking platform. Glycine was then added to a final
concentration of 0.125M for 5min. The cells werewashed twice
with ice-cold phosphate-buffered saline before being scraped
off the plate with 5 mM EDTA in phosphate-buffered saline.
The cells were then pelleted and washed with ice-cold phos-
phate-buffered saline. The pellet was resuspended in 500 l of
cell lysis buffer (5 mM PIPES, pH 8.0, 85 mM KCl, 0.5% Nonidet
P-40) and incubated on ice for 10 min. The sample was centri-
fuged, and the supernatant was removed. The nuclei were then
lysed by adding 1 ml of nuclei lysis buffer (50 mM Tris-Cl, pH
8.1, 10 mM EDTA, 1% SDS) and incubating on ice for 10 min.
The samples are then sonicated on setting 3 (Sonic Dismem-
brator 550; Fisher), four pulses of 15 s, separated by 30 s. The
sonicated chromatin was then precleared by rotating at 4 °C for
2 h with normal rabbit IgG (2 g/ml), salmon sperm DNA (20
g/ml), and 40 l of protein A/G-agarose beads (Santa Cruz
Biotechnology) that had been prewashed with dialysis buffer (2
mM EDTA, 50 mM Tris-Cl, pH 8.0, 0.2% Sarkosyl), followed by
brief centrifugation. For the immunoprecipitation, 200l of the
precleared sample was diluted with 400 l of dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
Cl, pH 8.1, 167 mM NaCl). The sample was then rotated over-
night at 4 °C with 2 l of normal rabbit serum or 5 l of rabbit
polyclonal AR antibody (Upstate Biotechnology, Inc.). Protein
A/G-agarose beads that had been prewashed with dialysis
buffer were added, and the samples were rotated at 4 °C for 2 h.
The samples were centrifuged briefly, and the resulting pellet
was washed twice with dialysis buffer and four times with IP
wash buffer (100 mM Tris-Cl, pH 9.0, 500 mM LiCl, 1% Nonidet
P-40, 1% deoxycholic acid). Between washes, the samples were
rotated at 4 °C for 3 min. To the pellet, 150 l of elution buffer
(50 mM NaHCO3, 1% SDS) was added, and the samples were
shaken vigorously at room temperature for 15 min. The sam-
ples were centrifuged briefly, the supernatant was collected,
and the elution process was repeated. For input, 200 l of the
precleared DNA was diluted in 100 l of elution buffer. To the
pooled elutions and the input sample, NaCl (final concentra-
tion of 0.3 M) was added, and the samples were incubated at
67 °C overnight to decross-link. The DNA was ethanol-precip-
itated, and the protein was digested with proteinase K (Invitro-
gen). The DNA was purified using a PCR purification kit
(Qiagen). Thirty-five cycles of PCR were then performed
using 1 l of the chromatin as template. Primers for the
prostate-specific antigen enhancer were 5- CATGTTCACA-
TTAGTACACCTTGCC-3 and 5-TCTCAGATCCAGGCT-
TGCTTACTGTC-3. Primers for Clu 1, which encompasses
region 2094 to 2433 of the clusterin gene, were 5-CAG-
CCCTGCAGTGATTCATA-3 and 5-CCCGACCCCTAG-
TCCAGTAT-3. Primers for Clu 2, which encompasses
region2443 to2761, were 5-CTCTACTCCCAGGGTTA-
CCA-3 and 5-CCCCTGAAAGCAACAACTTC-3. Primes
for Clu 3, encompassing 2779 and 3083 of the gene, were
5-TTCTGGCTGGCTTTGTCTCT-3 and 5-GTTCCCCT-
TCCTGAAATGGT-3.
LNCaPXenografts—2 106 cultured LNCaP cells were com-
bined withMatrigel (BD Biosciences) at a 50:50 volume ratio of
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cells to Matrigel and injected subcutaneously into four sites of
6–8-week-old athymic nude mice (BALB/c strain; Charles
River Laboratory). The mice were surgically castrated 8 weeks
postinjection under methoxycluorane anesthesia. To harvest
the tumors, the mice were sacrificed using carbon dioxide
asphyxiation, and the tumors were removed and frozen imme-
diately at 80 °C. Androgen-
dependent tumors were harvested
8–14 days postcastration, whereas
AI tumors were harvested 22–35
days postcastration.
Statistical Analysis—The error
bars in the real timePCRgraphs (see
Figs. 1 and 4–6) represent S.E. The
luciferase data were analyzed using a
Kruskal-Wallis nonparametric test,
followed byDunn’smultiple compar-
ison test to determine statistically sig-
nificant differences between EtOH-
and R1881-treated samples using
Prism (GraphPad). For the real time
PCR, statistical significance was
measured using a Student’s t test
(Microsoft Excel).
RESULTS
Clusterin is Up-regulated by
Androgens in a Dose- and Time-de-
pendent Manner—To determine if
clusterin levels are affected by
androgens in vitro, LNCaP cells
were treated with 1 nM R1881 for a
time period ranging from 16 to 72 h.
Northern blot analysis of those samples reveals that when com-
pared with the time-matched vehicle control, the levels of clus-
terin mRNA increase with androgen treatment starting at 36 h
and continue to rise up to and including 72 h (Fig. 1A). Real time
PCR was used to quantify the increase of clusterin levels in
response to androgens (Fig. 1B). DNA laddering analysis of the
androgen-treated cells revealed no apparent increase in apo-
ptosis over the time period when clusterin levels increase (data
not shown). To verify that the response being seen is dose-de-
pendent, LNCaP cells were treated with R1881 for 72 h in doses
ranging from 0.01 to 10 nM. There is no detectable response to
low levels of androgens up to 0.1 nM R1881. Clusterin mRNA
levels increase in cells treated with levels of R1881 greater
than 1 nM (Fig. 1C). A similar increase in clusterin mRNA
levels was seen with 10 nM DHT (data not shown).
We were interested in determining if clusterin was also up-
regulated by androgens in the rat prostate. The rat ventral pros-
tate is highly androgen-responsive and has been used to study
the effects of androgen withdrawal and as a model to study
androgen-regulated genes. Young male Sprague-Dawley rats
were castrated for 7 days, and prostates were removed, micro-
dissected, and grown in organ culturewith orwithout androgen
treatment for 24 h. RNA was harvested and analyzed for a vari-
ety of genes (38, 39). In these ex vivo prostate samples, the levels
of clusterin RNA increased in the prostate organ culture follow-
ing treatmentwithDHT (Fig. 1D). This finding shows that clus-
terin is also up-regulated in the normal prostate secretory epi-
thelium in response to androgens.
To verify that levels of clusterin protein corroborate the
increase detected at the mRNA level, protein from androgen-
treated LNCaP cells was harvested and probed byWestern blot.
FIGURE 1. Clusterin mRNA levels in response to androgen treatment. A, top, Northern blot of an R1881
time course probed for clusterin; bottom, loading control. LNCaP cells were treated with 1 nM R1881 () or
ethanol vehicle () for periods of time ranging from 16 to 72 h. B, real time PCR quantification of clusterin
mRNA levels in response to androgen treatment. The graph shows the ratio of clusterin mRNA in R1881-
treated cells to vehicle control-treated cells. C, Northern blot of R1881 titration. LNCaP cells were treated
with doses of R1881 ranging from 0.01 to 10 nM R1881 for a time period of 72 h. D, the ventral prostates
from 7-day castrated adult rats were minced into small pieces and cultured in dish, as described. After
overnight culture, the prostates were treated with DHT at a final concentration of 1 M or ethanol vehicle
for 24 h. The tissues from organ culture were then harvested and isolated for Northern blot analysis. The
lower panel shows the methylene blue staining pattern, indicating the amount and quality of total RNA
loaded in each lane.
FIGURE 2. Clusterin protein levels in response to androgen treatment.
A, top, Western blot of an R1881 time course probed for clusterin; bottom,
-tubulin levels as a loading control. LNCaP cells were treated with 1 nM
R1881 () or ethanol vehicle () for periods of time ranging from 16 to 72 h.
Shown are both the 60-kDa (full-length) and 40-kDa (processed) forms of
clusterin. B, Western blot of R1881 titration. LNCaP cells were treated with
doses of R1881 ranging from 0.01 to 10 nM R1881 for 72 h.
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A time course of androgen treatment is shown in Fig. 2A. In the
absence of treatment, there are low levels of clusterin expres-
sion in LNCaP cells. With increasing duration of androgen
treatment, the levels of clusterin increase starting at 36 h and
continuing through to 72 h. The antibody used in the Western
blots detects the-chain of clusterin. The two bands seen in the
Western blots are the 60-kDa form and the 40-kDa cleaved
form of clusterin. Both the 40- and 60-kDa bands are seen
increasing beginning at 36 h. The dose responsiveness of the
clusterin is highly similar to that seen at the mRNA level, dra-
matically increasing with exposure of R1881 at 1 nM and above
(Fig. 2B).
The AR Is Necessary for Clusterin to Be Up-regulated—To
prove that AR mediates the up-regulation of clusterin, LNCaP
cells were treated with R1881 alone or in conjunction with the
AR-antagonist casodex for 48–72 h. At all time points tested,
casodex was able to completely block the effect of R1881 up-
regulation of clusterin (Fig. 3, A and B). The AR belongs to the
steroid receptor subclass of nuclear receptors, which also
includes ER, progesterone receptor, glucocorticoid receptor,
and mineralocorticoid receptor (40). Nuclear receptors are
structurally similar, containing a C-terminal ligand binding
domain, a central DNA binding domain, and an N-terminal
transactivation domain (41). It is possible that the response to
androgens is not specific and that other steroid receptors and
their cognate hormones could also
regulate clusterin expression. To
test this possibility, LNCaP cells
were transfected with specific hor-
mone receptors and treated with
their respective ligands to examine
whether the effect being seen is con-
fined to androgens (Fig. 3C). The
exogenous expression of receptors
alone had no effect on clusterin lev-
els; nor was there a noticeable effect
on themRNA levels (Fig. 3C) or pro-
tein levels (data not shown) when
the receptor-transfected cells were
ligand-activated. These data dem-
onstrate that an increase in clusterin
levels is mediated specifically by AR
and not other steroid receptors in
LNCaP cells.
The First Intron of the Clusterin
Gene Contains Functional AREs—It
has been reported previously that
the first intron of human clusterin
contained putative AREs to which
the AR may bind (42, 43). To exam-
ine this further in our studies, the
first intron was analyzed using Con-
site software,whichpredicts response
elementswithin aDNAsequence and
has shown the reliable prediction of
validated AREs (44). Many AREs
were predicted; however, a cluster
of AREs was found between 2595
and 3211 of the clusterin gene (Fig. 4A). It has been shown
previously that for maximal androgen responsiveness, AREs
function cooperatively (45, 46); therefore, it is likely that the
androgen-responsive region in the intron lies within the cluster
of AREs. Two luciferase reporter constructs were made, both of
which encompassed the region high in putative AREs. The
reporter construct termedT21 contained the region high inAREs
in addition to the region 5, whereas the T23 construct contained
the region high in putative AREs as well as the region 3 to this.
Both constructs were tested in luciferase assays done both in
LNCaP and PC3 cells. As a positive control, the same amount of
a luciferase reporter construct with the promoter region of the
prostate-specific antigen (PSA) was used in parallel.
In LNCaP cells, the T21 construct was more responsive to
androgens than the T23 construct and slightlymore active than
the PSA proximal promoter construct (Fig. 4B). This suggests
that theremay be AREs or other elements on the DNA 5 to the
region encompassed by both T21 and T23, which can further
enhance the activity of the DNA. In PC3 cells transfected with
AR, T21 has similar transcriptional activity as PSA in
response to androgens; however, T23 shows no activity at all
(Fig. 4C). The difference in the activity of the T23 construct
between LNCaP and PC3 cells shows that the response is
modulated by cell type and could require additional tran-
scription factors.
FIGURE 3. Necessity of AR in clusterin up-regulation. A, Northern blot showing that the up-regulation of
clusterin is blocked by casodex, an AR antagonist. LNCaP cells were treated with 1 nM R1881 alone or in
conjunction with 1 M casodex for periods of time ranging from 48 to 72 h. B, Western blot showing that
casodex also blocks androgen action on clusterin at the protein level. C, LNCaP cells were transfected with the
steroid receptors AR, glucocorticoid receptor (GR), ER, progesterone receptor (PR), thyroid hormone receptor
(TR), and retinoic acid receptor (RAR) and then treatedwith a 1 nM concentration of the cognate ligand (R1881,
dexamethasone, estradiol, progesterone, 3,3,5-triiodo-L-thyronine sodium salt or all-trans-retinoic acid,
respectively). Shown are Northern blots of these samples, probed for clusterin.
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To verify that AR is binding to the clusterin intron in vivo,
chromatin immunoprecipitation (ChIP) was performed (Fig.
5C). The chromatin fromLNCaP cells that had been cultured in
the presence or absence of R1881 for 2 or 48 hwas immunopre-
cipitatedwith either normal rabbit serum, as a negative control,
or with an AR antibody. As a positive control, PCR was per-
formed on a region of the PSA enhancer known to be bound by
AR. At the 2-h time point, there is more PSA enhancer PCR
product in the R1881-treated sample than the ethanol control,
showing that there is more AR
bound. Three regions of the clus-
terin intron were assayed. There is
no binding of AR observed in the
regions ofClu 1 andClu 3. In theClu
2 region, however, there is more
PCR product in the R1881-treated
samples with a 48 h duration of
treatment.
Differential Regulation of Clus-
terin Isoforms—In primates, there
are two transcriptional isoforms of
clusterin resulting from two inde-
pendent transcriptional start sites
(Fig. 5A). It is predicted that in
humans, the two isoforms differ in
their translational start sites, with
Isoform 1 translating the first exon,
whereas Isoform 2, whose tran-
scriptional start site is in Intron 1,
initiates translation in Exon 2. How-
ever, all available clusterin antibod-
ies recognize the epitopes of the
protein, which are common to both
isoforms and are therefore not able
to distinguish between isoforms.
Since the ARE-containing region in
the first intron is located between
the two transcriptional start sites,
we were interested in determining
whether androgens can regulate the
transcription of one or both iso-
forms. Primers and probes for real
time PCR were designed to the
unique 5-untranslated regions of
the two isoforms to measure their
individual transcriptional levels.
Interestingly, Isoform 2 is up-regu-
lated by androgens by 24 h and is
maintained throughout the 48-h
time period, whereas Isoform 1 is
down-regulated by androgens (Fig. 5,
B–E). The up-regulation of total clus-
terin mRNA levels is not observed
until 48 h, suggesting that at 24 h, the
up-regulation of the Isoform 2 is
masked by the down-regulation of
Isoform 1, and there is no observable
change in total clusterin levels.
The LNCaP xenograft tumor model is often used as a model
for progression from androgen dependence to androgen inde-
pendence. In this model, androgen-regulated genes, such as
PSA, respond to castration by being down-regulated following
castration up to about day 21. However, during progression to
androgen independence, androgen-regulated genes, including
PSA, are reactivated by about day 28 and remain elevated in AI
tumors. To determine the kinetics of clusterin expression dur-
ing progression to androgen independence, tumors from an
FIGURE4.Transcriptional activationdue toAR interactionwithanenhancer regionwithin the first intron
of the clusterin genomic DNA. A, the clusterin gene and constructs made from it for the purposes of the
luciferase assay and ChIP. The asterisk denotes the region containing clusters of putative AREs. B, lucifer-
ase assay in LNCaP cells. The LNCaPs were transfected with the reporter constructs, the Renilla construct,
and an AR expression plasmid. The cells were treated with 0, 0.1, 1, and 10 nM R1881. PSA is included as a
positive control. An asterisk indicates that the value is significantly different from the EtOH value (p value
0.05). C, luciferase assay in PC3 cells. The PC3 cells were transfected with the reporter constructs, the
Renilla construct, and an AR expression plasmid. The cells were treatedwith 0, 0.01, 0.05, and 0.1 nM R1881.
An asterisk indicates that the value is significantly different from the EtOH value (p value 0.05). D, PCR
products from ChIP assay. The cells were treated for 2 or 48 h, with (R) or without (E) 1 nM R1881. Immu-
noprecipitation using rabbit serum was a negative control showing background levels of the PCR prod-
ucts. PSA was a positive control for AR binding. Clu 1, Clu 2, and Clu 3 are three regions within the clusterin
first intron containing putative AREs.
Regulation of Clusterin by Androgens
JANUARY 26, 2007•VOLUME 282•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2283
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
LNCaP tumor series were harvested for RNA. A Northern blot
of PSA levels in the tumors prior to and following castration is
shown (Fig. 6A), and the corresponding serum PSA levels are
shown in Fig. 6B. The tumor volumes of the tumors are shown
in Fig. 6C. Unlike normal prostate cells, LNCaP tumors do not
undergo apoptosis in response to castration. The tumor vol-
FIGURE5.Androgenicregulationofthetwoclusterin isoforms.A, theclusteringeneandthetwomRNAtranscripts formedfromalternate transcriptional start sites.
The clusteringene ispicturedwith theexonsappearingasnumberedboxesand the intronsnumbered in romannumerals. The locationsof real timePCRprimersused
to distinguish the two isoforms are indicated on the clusterin gene asQPCR. The bent arrows show the translational start sites on themRNAs. Splicing out of exon 2
results in thenuclear isoformofclusterin.TheERtargetingsignal is found inexon2,andthenuclear localizationsignal (NLS) is found inexon3.LNCaPcellswere treated
with1nMR1881 for 24or 48h. RNA fromthe cellswas assayed for clustering Isoform1and Isoform2 levels using real timePCR. Shownare clusterin Isoform1 levels at
24 h (B) and 48 h (C) of treatmentwith R1881. Levels of clusterin Isoform 2 levels at 24 h (D) and 48 h (E) are shown. *, p 0.05.UTR, untranslated region.
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umes instead cease growing until AI, where proliferation con-
tinues. Real time PCRwas used to determine transcript levels of
clusterin and its two isoforms. PSA is shown as a positive con-
trol, and its levels increase with progression (Fig. 6B). Both total
clusterin and Isoform 1 levels increase moderately with pro-
gression to androgen independence (Fig. 6, C and D); however,
the increase is not statistically significant. Isoform 2 levels do
show a significant increase in levels at androgen independence
as compared with androgen dependence (Fig. 6E), consistent
with the androgen regulation of this isoform.
PCR has been used previously to detect the nuclear splice
variant (21). Such PCR did not reveal the presence of the
nuclear splice variant of clusterin (data not shown); however,
neither androgen treatment in vitro nor progression to andro-
FIGURE 6. Levels of clusterin isoforms in androgen-dependent and -independent LNCaP xenografts. LNCaP cells were injected subcutaneously into
athymicmice, and tumors were harvested prior to castration and at various time points after castration. A, Northern blots showing the PSA levels in the LNCaP
tumors as it progressed to androgen independence. The serumPSA (B) and the tumor volume (C) of the tumor series is also shown. ThemRNA levels of PSA (D),
total clusterin (E), clusterin Isoform 1 (F), and Isoform 2 (G) were determined using real time PCR for androgen dependence (AD) (using day 8 samples) or
androgen independence (AI) (using day 35 samples). *, p 0.05.
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gen independence in the LNCaP tumor model is expected to
have nuclear, apoptotic clusterin expressed.
DISCUSSION
Levels of clusterin increase dramatically in the rat ventral
prostate upon castration, leading to its designation as a testos-
terone-repressed message. Later studies demonstrated that the
increase in clusterin was most likely a stress response brought
about by castration-induced apoptosis of the prostatic epithe-
lial cells and is perhaps regulated in concert with the heat shock
proteins (16, 47). The androgenic regulation of clusterin has
been primarily studied in vivo by removal of androgens by phys-
ical or hormonal castration of rats or onmice bearing xenograft
tumors (12, 49, 50). However, in this context, it is difficult to
dissociate the androgenic and the apoptotic stimuli. In the
Shionogi tumormodel, apoptosis is blocked by calciumchannel
blockers, and clusterin levels do not increase upon castration
(14). Therefore, studying the effects of androgens on prostate
cells in cell culture and in organ culture avoids the confounding
influence of the multiple signals present in the in vivo system.
In the present study, we have demonstrated that in both
human prostate cancer cells and in the rat ventral prostate, total
clusterin is in fact up-regulated by androgens. Androgen treat-
ment causes an increase in the levels of both the total clusterin
mRNAand the resulting protein, clusterin. The effect seen is both
time- and dose-dependent while independent of apoptosis.
Androgens are necessary for the growth and differentiation
of normal prostatic epithelium. It has been shown that clusterin
plays a role in many different types of cancer as a cell survival
factor and helps cancerous cells to evade stress-induced apo-
ptosis. We propose herein that clusterin may also play a cyto-
protective role in normal prostate cells under the regulation of
androgens. Androgens themselves have long been known to
promote survival of prostatic epithelium, and they appear to
increase the cell’s ability to withstand apoptotic stimuli (47).
Androgens have been shown to play a cytoprotective role by
decreasing the levels of proapoptotic proteins, such as the
caspases and members of the Bcl-2 family of proteins (51, 52), as
well as preventing the release of cytochrome c from themitochon-
dria (53). It is therefore not surprising that androgens could
increase the levels of antiapoptotic proteins, such as clusterin,
which would act to protect prostate cells against apoptosis.
The transcriptional regulation of the clusterin gene is prob-
ably quite complex. When a cell undergoes a stress response to
stimuli, such as heat shock, clusterin is induced. It was shown
that in this scenario, the heat shock transcription factor, HSF-1,
binds to a heat shock element in the 5 promoter region of the
murine clusterin gene and induces its expression (54). In addi-
tion to stress induction, there are various growth factors that
can induce clusterin expression, including transforming
growth factor , nerve growth factor, and epidermal growth
factor (55–57). These growth factors have been shown to
require an AP-1 site found in the 5-proximal promoter region
of the clusterin gene to induce its expression.
Other steroid hormones have been shown to have effects on
clusterin expression in other cell types. A number of studies
have reported that estradiol treatment can cause an increase or
decrease of clusterin levels in the uterus and endometrium
(58–60). Also, vitamin D has been shown to increase clusterin
levels in human breast cancer MCF-7 cells (61, 62). Although
these steroids have been implicated in clusterin regulation,
there has not been shown to be direct interaction of the cognate
steroid receptor with the clusterin gene, and these are possibly
downstream effects. In contrast, we have shown that the AR
does interactwith a regulatory region found in the first intron of
the clusterin gene and increases the transcription of clusterin in
prostate epithelial cells.
It has been postulated that there are AREs within the first
intron of both the rat and human clusterin genes and that the
AR could bind to these response elements and repress the
expression of clusterin (42, 43, 63).We have shown that the AR
does bind specifically to the clusterin intronicDNA, resulting in
an increase in transactivation in a reporter assay. The ChIP
assay demonstrated that although AR does bind a region of the
clusterin first intron in vivo, binding does not occur at 2 h post-
androgen treatment as it does for the PSA enhancer region.
Rather, AR binding occurs later, within 48 h after androgen
treatment. We therefore hypothesize that there may be repres-
sor proteins at play that prevent AR from binding or other pos-
itive acting factors or chromatin remodeling needed for AR to
bind and initiate assembly of a transcription complex.
AR is known to induce transcriptional activity through inter-
action with AREs. However, there is little known about its abil-
ity to directly cause transcriptional repression. Therefore, it is
unclear as to whether the direct interaction of AR with the
intronic region of clusterin is the cause of the down-regulation
of Isoform 1 or if this is an effect of transcriptional interference.
The differential regulation of two clusterin isoforms may be
critical to regulation of the opposing apoptotic and antiapopto-
tic functions of the two isoforms. Both isoforms are cytoprotec-
tive4; however, Isoform 1 has the capacity to produce the
nuclear, apoptotic form of clusterin generated by alternative
splicing (21). In the context of androgens, which are cytopro-
tective in prostate cells, we show that androgens specifically
up-regulate Isoform 2 of clusterin while down-regulating Iso-
form 1. Studies performed in other species demonstrate the
antiapoptotic nature of clusterin, and interestingly these other
species only produce an orthologue equivalent to Isoform 2,
since they lack an initiating methionine in the first exon.
Isoform 2 is shown to increase during progression to andro-
gen independence in LNCaP xenograft tumors, and this corre-
lateswith the induction of PSA at androgen independence. This
is consistent with Isoform 2 being an androgen-regulated gene,
since there is a reactivation of AR signaling at androgen inde-
pendence, demonstrated by the recurrence of PSA and other
androgen-regulated genes (64, 65). AR remains important as
tumors progress to androgen independence, and as such these
tumors retain high expression levels of AR (66), and down-
regulation of AR using small interfering RNA causes an
increase in apoptosis (48). Therefore, as prostate tumors pro-
gress to androgen independence, the reactivation in AR signal-
ing is functionally important for maintenance of cell viability.
Clusterin is also important for evasion of apoptosis during pro-
gression to androgen independence (24, 31). In that context, AI
prostate cells will seek to up-regulate the antiapoptotic form of
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clusterin and, as such, will up-regulate Isoform 2, which cannot
be spliced into the apoptotic form.
The data presented herein suggest that androgens may be
cytoprotective in secretory prostatic epithelial cells in humans
in part through up-regulation of clusterin Isoform 2 and down-
regulation of clusterin Isoform 1. This is not only important in
the maintenance of normal prostate but also during the pro-
gression to androgen-independent prostate cancer.
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